1/76
Comprehensive vocabulary flashcards covering the key enzymes, pathways, clinical disorders, and regulators discussed across Sessions 46 to 53 of Metabolic Biochemistry.
Triglycerides (TAGs)
Primary energy storage molecules in adipose tissue yielding ∼9kcal/g, composed of a glycerol backbone esterified to three fatty acid chains via ester linkages.
Colipase
A protein cofactor that assists pancreatic lipase in the intestinal lumen to hydrolyze dietary triglycerides into 2-monoglycerides (2-MAG) and free fatty acids (FFAs).
Lipoprotein Lipase (LPL)
An enzyme anchored to the capillary endothelium in adipose, skeletal, and cardiac muscle that is activated by ApoC-II to hydrolyze triglycerides within circulating chylomicrons and VLDL into FFAs and glycerol.
Adipose Triglyceride Lipase (ATGL)
The rate-limiting intracellular lipolysis enzyme in adipocytes that hydrolyzes a triglyceride into diacylglycerol (DAG) and one free fatty acid; transcriptionally regulated by PPARγ and activated by cofactor CGI-58.
Hormone-Sensitive Lipase (HSL)
An intracellular adipocyte enzyme that hydrolyzes diacylglycerol to monoacylglycerol and one free fatty acid; activated via PKA phosphorylation (stimulated by catecholamines, glucagon, ACTH) and inactivated by insulin-stimulated dephosphorylation.
HMG-CoA Reductase
The rate-limiting enzyme in cholesterol biosynthesis located in the cytoplasm/ER that converts HMG-CoA into mevalonate utilizing 2NADPH.
SREBP2
A sterol regulatory element-binding transcription factor that, when intracellular sterols are low, is escorted by SCAP from the ER to the Golgi for proteolytic cleavage, releasing an active domain that upregulates HMG-CoA reductase and LDL receptor transcription.
ACAT (Acyl-CoA:Cholesterol Acyltransferase)
An intracellular enzyme that synthesizes cholesteryl esters from free cholesterol and fatty acyl-CoA for cellular storage in lipid droplets.
LCAT (Lecithin:Cholesterol Acyltransferase)
A plasma enzyme activated by ApoA-I on HDL that transfers a fatty acid from phosphatidylcholine to free cholesterol, forming hydrophobic cholesteryl esters inside HDL.
Cholesterol 7α-Hydroxylase (CYP7A1)
The rate-limiting enzyme in hepatic bile acid synthesis that converts cholesterol into primary bile acids (cholic acid and chenodeoxycholic acid).
Statins
Competitive inhibitors of HMG-CoA reductase structurally analogous to the HMG-CoA/mevalonate transition state, lowering intracellular hepatic cholesterol and upregulating hepatocyte LDL receptor expression.
Chylomicrons
The lowest-density (<0.95g/mL) lipoproteins composed of ∼90% dietary triglycerides and containing ApoB-48, ApoA-I, ApoC-II, and ApoE, responsible for transporting dietary lipids to peripheral tissues.
VLDL (Very Low-Density Lipoprotein)
A lipoprotein (0.95−1.006g/mL) synthesized by the liver containing ∼60% endogenous triglycerides and apoproteins ApoB-100, ApoC-II, and ApoE.
LDL (Low-Density Lipoprotein)
A cholesterol-rich lipoprotein (1.019−1.063g/mL) composed of ∼50% cholesteryl esters and ApoB-100 that delivers cholesterol to peripheral tissues and the liver via LDLR endocytosis.
HDL (High-Density Lipoprotein)
The highest-density (1.063−1.210g/mL) lipoprotein containing ∼50% protein (ApoA-I, ApoA-II, ApoC, ApoE) and phospholipids that mediates reverse cholesterol transport.
CETP (Cholesteryl Ester Transfer Protein)
A plasma protein that mediates the reciprocal exchange of cholesteryl esters from HDL for triglycerides from VLDL and IDL.
PCSK9
A circulating protein that binds cell-surface LDL receptors and directs them toward lysosomal degradation, preventing receptor recycling back to the hepatocyte membrane.
Familial Hypercholesterolemia (FH)
An autosomal dominant disorder most commonly caused by loss-of-function mutations in the LDLR gene, resulting in impaired hepatic LDL clearance, xanthomas, and premature atherosclerosis.
Pyridoxal Phosphate (PLP)
The active cofactor form of vitamin B6 that forms a covalent Schiff base intermediate with amino acids during transamination reactions via a ping-pong, bi-bi mechanism.
Carbamoyl Phosphate Synthetase I (CPS-I)
The rate-limiting mitochondrial enzyme of the urea cycle that condenses free NH4+, HCO3−, and 2ATP into carbamoyl phosphate; strictly requires N-acetylglutamate (NAG) for allosteric activation.
N-Acetylglutamate (NAG)
An obligatory allosteric activator of carbamoyl phosphate synthetase I (CPS-I), synthesized by NAG synthase when stimulated by arginine, glutamate, and acetyl-CoA.
Glutamate Dehydrogenase
A mitochondrial enzyme in the liver and kidney that oxidatively deaminates glutamate using NAD+ to release free NH4+ and regenerate α-ketoglutarate; activated by ADP/GDP and inhibited by ATP/GTP.
Transdeamination
The sequential pathway coupling aminotransferase transamination (transferring amino groups onto α-ketoglutarate to yield glutamate) with glutamate dehydrogenase oxidative deamination to liberate free ammonia for the urea cycle.
S-Adenosylmethionine (SAM)
The universal activated methyl donor formed from methionine and ATP, which yields S-adenosylhomocysteine (SAH) and ultimately homocysteine upon methyl group transfer.
Phenylketonuria (PKU)
An autosomal recessive aminoacidopathy caused by deficiency of phenylalanine hydroxylase (or BH4), resulting in elevated phenylalanine, musty body odor, hypopigmentation, and intellectual disability.
Maple Syrup Urine Disease (MSUD)
An inherited defect in the branched-chain α-ketoacid dehydrogenase complex that prevents degradation of leucine, isoleucine, and valine, resulting in neurotoxicity and sweet-smelling, maple-syrup-like urine.
Alkaptonuria
An inherited metabolic disorder caused by deficiency of homogentisate 1,2-dioxygenase, leading to homogentisic acid accumulation, urine that turns dark/black on standing, ochronosis, and severe arthritis.
ALA Synthase (ALAS)
The committed and rate-limiting mitochondrial enzyme of heme biosynthesis that condenses glycine and succinyl-CoA using PLP to form 5-aminolevulinic acid (ALA).
Ferrochelatase
The final mitochondrial enzyme of heme biosynthesis that inserts ferrous iron (Fe2+) into protoporphyrin IX to form heme; directly inhibited by lead.
Bilirubin Diglucuronide
The conjugated, water-soluble form of bilirubin generated in hepatocytes by UDP-glucuronosyltransferase (UGT1A1) attaching two glucuronic acid molecules, allowing excretion into bile.
Porphyrias
A group of disorders caused by partial enzyme deficiencies in heme synthesis: accumulation of early non-cyclic precursors (ALA, PBG) causes neurovisceral attacks, whereas accumulation of light-absorbing porphyrinogens causes cutaneous photosensitivity.
Dihydrofolate Reductase (DHFR)
An NADPH-dependent enzyme that reduces oxidized folate or dihydrofolate (FH2) to the functional one-carbon carrier tetrahydrofolate (THF / FH4).
Thymidylate Synthase
The enzyme that converts dUMP to dTMP by transferring and reducing a one-carbon unit from N5,N10-methylene-THF, oxidizing THF to FH2.
Folate Trap
The clinical condition in vitamin B12 deficiency where folate is locked irreversibly as N5-methyl-THF due to inactive methionine synthase, impairing purine and dTMP synthesis.
Methotrexate (MTX)
A folate analog that competitively inhibits human dihydrofolate reductase (DHFR), depleting intracellular FH4 and halting DNA replication in rapidly dividing cells.
Glutamine Phosphoribosyl Amidotransferase
The committed enzyme of de novo purine nucleotide synthesis that transfers an amino group from glutamine to PRPP to form 5'-phosphoribosyl 1'-amine; feedback-inhibited by AMP and GMP.
Carbamoyl Phosphate Synthetase II (CPS-II)
The cytosolic rate-limiting enzyme in de novo pyrimidine synthesis that uses glutamine, CO2, and 2ATP to synthesize carbamoyl phosphate; inhibited by UTP and activated by PRPP.
Ribonucleotide Reductase (RR)
An enzyme that reduces ribonucleoside diphosphates (NDPs) to deoxyribonucleoside diphosphates (dNDPs) using the reducing power of thioredoxin.
Xanthine Oxidase
A purine catabolic enzyme that oxidizes hypoxanthine to xanthine, and xanthine to poorly soluble uric acid.
Lesch-Nyhan Syndrome
An X-linked recessive disorder caused by deficiency of HGPRT, impairing purine salvage and driving PRPP accumulation, de novo purine synthesis, hyperuricemia, choreoathetosis, and compulsive self-mutilation.
Allopurinol
A hypoxanthine structural analog that is metabolized to alloxanthine/oxypurinol to suicide-inhibit xanthine oxidase, treating hyperuricemia and gout by increasing excretion of soluble xanthine and hypoxanthine.
Triglycerides (TAGs)
Primary energy storage molecules composed of a glycerol backbone esterified to three fatty acid chains via ester linkages, yielding approximately 9kcal/g, providing thermal insulation, and cushioning organs.
Lipoprotein Lipase (LPL)
An enzyme anchored to the capillary endothelium in adipose tissue and skeletal/cardiac muscle that is activated by ApoC-II to hydrolyze triglycerides within circulating chylomicrons and VLDL into free fatty acids and glycerol.
Adipose Triglyceride Lipase (ATGL)
The rate-limiting intracellular lipase in adipocytes that initiates lipolysis by converting triglycerides to diacylglycerol (DAG) and a free fatty acid; transcriptionally regulated by PPARγ and directly activated by the cofactor CGI-58.
Hormone-Sensitive Lipase (HSL)
An intracellular adipocyte enzyme that converts diacylglycerol to monoacylglycerol and a free fatty acid; activated via PKA-dependent phosphorylation (stimulated by catecholamines, glucagon, and ACTH) and inactivated via dephosphorylation (stimulated by insulin).
HMG-CoA Reductase
The committed, rate-limiting enzyme in cholesterol biosynthesis that reduces HMG-CoA to mevalonate; transcriptionally upregulated by SREBP2, allosterically/competitively inhibited by statins, and covalently inactivated by AMPK phosphorylation.
SREBP2
A transcriptional regulator that, under low sterol conditions, is escorted by SCAP from the ER to the Golgi for proteolytic cleavage, releasing an active N-terminal domain that enters the nucleus to upregulate transcription of HMG-CoA reductase and the LDL receptor.
Cholesterol 7α-Hydroxylase (CYP7A1)
The rate-limiting enzyme of bile acid synthesis that catalyzes the conversion of cholesterol into primary bile acids (cholic acid and chenodeoxycholic acid).
Statins
Structural analogs of the HMG-CoA/mevalonate transition state that act as competitive inhibitors of HMG-CoA reductase, thereby depleting intracellular hepatic cholesterol, triggering SREBP2 activation, and upregulating hepatic LDL receptors.
Chylomicrons
The lowest-density lipoproteins (<0.95g/mL) containing ApoB-48, ApoA-I, ApoC-II, and ApoE that transport dietary triglycerides (∼90%) from the intestines to peripheral tissues via lymphatic lacteals and the thoracic duct.
Very-Low-Density Lipoprotein (VLDL)
A liver-derived lipoprotein (0.95–1.006g/mL) containing ApoB-100, ApoC-II, and ApoE that packages and delivers endogenous liver-synthesized triglycerides (∼60%) to peripheral tissues.
High-Density Lipoprotein (HDL)
The highest-density lipoprotein (1.063–1.210g/mL) containing ApoA-I, ApoA-II, ApoC, and ApoE (∼50% protein) that mediates reverse cholesterol transport from peripheral tissues back to the liver and serves as an apoprotein reservoir.
Cholesteryl Ester Transfer Protein (CETP)
A plasma transport protein that transfers cholesteryl esters from HDL to VLDL and IDL in exchange for triglycerides.
PCSK9
A protein that binds to cell-surface LDL receptors and targets them for lysosomal degradation rather than recycling back to the cell membrane.
Familial Hypercholesterolemia (FH)
An autosomal dominant disorder caused primarily by loss-of-function mutations in the LDLR gene, resulting in impaired hepatic LDL clearance, marked elevations in plasma LDL-C, tendon xanthomas, corneal arcus, and premature atherosclerosis via macrophage foam cell accumulation.
Pyridoxal Phosphate (PLP)
The active coenzyme derived from vitamin B6 that mediates transamination reactions via a ping-pong, bi-bi mechanism, forming a Schiff base intermediate and transiently converting to pyridoxamine phosphate (PMP) to transfer amino groups.
Carbamoyl Phosphate Synthetase I (CPS-I)
The rate-limiting mitochondrial enzyme of the urea cycle that condenses NH4+, HCO3−, and 2ATP to synthesize carbamoyl phosphate; obligatorily requires N-acetylglutamate (NAG) as an allosteric activator.
N-Acetylglutamate (NAG)
The obligatory allosteric activator of carbamoyl phosphate synthetase I (CPS-I); synthesized by NAG synthase, which is stimulated by arginine and high concentrations of glutamate and acetyl-CoA.
Transdeamination
The coupled metabolic pathway wherein aminotransferases collect nitrogen from amino acids into glutamate, followed by the oxidative deamination of glutamate by glutamate dehydrogenase to release free ammonia (NH4+) for the urea cycle.
Glutamate Dehydrogenase
A mitochondrial enzyme in the liver and kidney that oxidatively deaminates glutamate to release free NH4+ and regenerate α-ketoglutarate, using NAD+ (for deamination) or NADPH (for amination); inhibited by ATP and GTP and activated by ADP and GDP.
S-Adenosylmethionine (SAM)
The universal activated methyl donor formed from methionine and ATP; after transferring its methyl group, it forms S-adenosylhomocysteine (SAH), which hydrolyzes to homocysteine and adenosine.
Phenylketonuria (PKU)
An inborn error of metabolism caused by a deficiency in phenylalanine hydroxylase (or its cofactor BH4), resulting in accumulation of phenylalanine and phenylketones, untreated intellectual disability, hypopigmentation, and a musty body odor.
Maple Syrup Urine Disease (MSUD)
An autosomal recessive disorder caused by a defect in the branched-chain α-ketoacid dehydrogenase complex, leading to the accumulation of leucine, isoleucine, valine, and their corresponding α-ketoacids, causing encephalopathy and a sweet, burnt-sugar urine odor.
Alkaptonuria
An autosomal recessive deficiency of homogentisate 1,2-dioxygenase, resulting in the accumulation of homogentisic acid, urine that turns dark/black on standing, ochronosis (blue-black cartilage pigmentation), and debilitating arthritis.
Homocystinuria
An inherited defect in cystathionine β-synthase, causing elevated levels of homocysteine and methionine, thromboembolism, downward lens dislocation (ectopia lentis), and a marfanoid habitus.
δ-Aminolevulinic Acid Synthase (ALA Synthase / ALAS)
The committed, rate-limiting mitochondrial enzyme of heme biosynthesis that condenses glycine and succinyl-CoA using PLP to form 5-aminolevulinic acid; ALAS1 (liver) is feedback-inhibited by heme/hemin (Fe3+), while ALAS2 (erythroid) is regulated by iron availability.
UDP-Glucuronosyltransferase (UGT1A1)
The hepatocyte enzyme that transfers two glucuronic acid molecules to hydrophobic unconjugated bilirubin, producing water-soluble bilirubin diglucuronide (conjugated bilirubin) for secretion into bile.
Acute Intermittent Porphyria (AIP)
An inherited disorder caused by porphobilinogen (PBG) deaminase deficiency, causing accumulation of non-cyclic precursors (ALA and PBG) that trigger neurovisceral attacks (abdominal pain, neuropsychiatric symptoms) without cutaneous photosensitivity.
Dihydrofolate Reductase (DHFR)
An enzyme that reduces dietary folate to dihydrofolate (FH2) and then tetrahydrofolate (FH4/THF) using NADPH; competitively inhibited by the antimetabolite drug methotrexate.
Thymidylate Synthase
An enzyme that converts dUMP to dTMP by transferring and reducing a one-carbon unit from N5,N10-methylene-THF, simultaneously oxidizing THF to FH2; suicide-inhibited by FdUMP (a metabolite of 5-fluorouracil).
Folate Trap
A condition occurring in vitamin B12 deficiency where cellular folate becomes trapped as N5-methyl-THF due to inactive methionine synthase, impairing purine and dTMP synthesis and causing megaloblastic anemia alongside neurological defects.
Glutamine Phosphoribosyl Amidotransferase
The committed enzyme of de novo purine synthesis that replaces the pyrophosphate group of PRPP with an amino group from glutamine to form 5'-phosphoribosyl 1'-amine; synergistically inhibited by AMP and GMP.
Carbamoyl Phosphate Synthetase II (CPS-II)
The cytosolic committed enzyme of de novo pyrimidine biosynthesis that consumes glutamine, CO2, and 2ATP to form carbamoyl phosphate; activated by PRPP and ATP, and inhibited by UTP.
Hypoxanthine-Guanine Phosphoribosyltransferase (HGPRT)
A purine salvage enzyme that reacts PRPP with hypoxanthine to produce IMP and with guanine to produce GMP.
Ribonucleotide Reductase (RR)
An enzyme that reduces ribonucleoside diphosphates (ADP, GDP, CDP, UDP) directly to deoxyribonucleoside diphosphates (dNDPs) at the 2' carbon position, using electrons supplied by the protein cofactor thioredoxin.
Xanthine Oxidase
A catabolic enzyme that catalyzes the sequential oxidation of hypoxanthine to xanthine, and xanthine to uric acid; competitively inhibited by allopurinol.
Lesch-Nyhan Syndrome
An X-linked recessive disorder caused by HGPRT deficiency, leading to decreased purine salvage, PRPP accumulation, accelerated de novo purine synthesis, hyperuricemia, gout, dystonia, intellectual disability, and compulsive self-mutilation.